Blue Jet Healthcare Ltd
NSE:BLUEJET
Blue Jet Healthcare Ltd
Blue Jet Healthcare Ltd is a IN-based company operating in industry. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2023-11-01. Blue Jet Healthcare Limited is an India-based specialty pharmaceutical and healthcare ingredients and intermediates company. The Company’s operations are primarily organized in three product categories: contrast media intermediates, high-intensity sweeteners, and pharma intermediates and active pharmaceutical ingredients (APIs). Contrast media are agents used in medical imaging to enhance the visibility of body tissues under X-rays, computed tomography (CT), magnetic resonance imaging (MRI) or ultrasound. Its high-intensity sweetener business includes development, manufacturing and marketing of saccharin and its salts. The Company’s contract development and manufacturing organization (CDMO) activity in the pharma intermediate and API business is primarily focused on collaborating with innovator pharmaceutical companies and multi-national generic pharmaceutical companies by providing them with pharma intermediates that serve as building blocks for APIs in chronic therapeutic areas.
Blue Jet Healthcare Ltd is a IN-based company operating in industry. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2023-11-01. Blue Jet Healthcare Limited is an India-based specialty pharmaceutical and healthcare ingredients and intermediates company. The Company’s operations are primarily organized in three product categories: contrast media intermediates, high-intensity sweeteners, and pharma intermediates and active pharmaceutical ingredients (APIs). Contrast media are agents used in medical imaging to enhance the visibility of body tissues under X-rays, computed tomography (CT), magnetic resonance imaging (MRI) or ultrasound. Its high-intensity sweetener business includes development, manufacturing and marketing of saccharin and its salts. The Company’s contract development and manufacturing organization (CDMO) activity in the pharma intermediate and API business is primarily focused on collaborating with innovator pharmaceutical companies and multi-national generic pharmaceutical companies by providing them with pharma intermediates that serve as building blocks for APIs in chronic therapeutic areas.
Revenue Drop: Quarterly revenue fell by 40% year-over-year, mainly due to customer destocking and supply chain realignment.
Margin Pressure: Gross margin decreased to 52%, impacted by product mix changes and a one-time inventory write-off.
Profit Decline: EBITDA declined 62% and PAT declined 39% year-over-year; both also fell sequentially.
CDMO & R&D Expansion: Significant investments underway in R&D and manufacturing capacity, including a new Vizag greenfield project (INR 1,000 crores over 3-4 years) and Hyderabad R&D center.
Contrast Media Progress: Key new products in Contrast Media are in validation or ramp-up, with positive volume outlook for FY '27.
Supply Chain Normalization: Management expects destocking effects and order normalization within 1-2 quarters.
Financial Flexibility: The company has INR 410 crores in cash and plans to fund near-term CapEx internally, with debt or equity as needed.
